| Study Short Title | Full Title | Name of PI | Dates | Status |
| BHIVA COVID-19 Registry | British HIV Association (BHIVA) COVID-19 Registry | Caroline Sabin | October 2020 - ongoing | Current |
| Association of HIV with outcomes of COVID-19 hospitalization outcomes | Outcomes of COVID-19-related hospitalization among people with HIV in the ISARIC World Health Organization (WHO) Clinical Characterization Protocol (UK) | Caroline Sabin | May 2020 - ongoing | Current |
| UK community survey of COVID/HIV | Community Survey of the experiences of COVID-19 on people living with HIV in the UK | Caroline Sabin | June 2020 - ongoing | Current |
| SEPAC | Screening and early detection to prevent anal cancer; development of a biomarker screening tool | Richard Gilson | April 2019 to March 2022 | Current |
| ASSIST | Assessing the impact of introducing online postal self-sampling for sexually transmitted infections into sexual health provision within the UK on health inequalities, access to care and clinical outcomes | Fiona Burns and Jo Gibbs | 1st January 2021 to 31st March 2024 | Current |
| SIREN (Sarscov2 Immunity & REinfection EvaluatioN) | Impact of detectable anti-SARS-COV2 on the subsequent incidence of COVID-19 in healthcare workers | Alejandro Arenas-Pinto | September 2020 to September 2022 | Current |
| Analysing immune responses to vaccination | Analysing humoral and cellular immune responses to vaccination during chronic infection | Dimitra Peppa, Richard Gilson, Laura Waters | October 2020 to October 2025 | Current |
| ICOS | International SARS-CoV-2 Infection Observational Study | Richard Gilson | 27th May 2020 - (ongoing) | Recruiting |
| Jenner II | Temporal analysis of host immune responses and mechanisms impairing control of viral replication of during the course of HIV-1 infection | Dimitra Peppa | | Recruiting |
| Chips+ | CHIPS+: Optimising the health of young people with HIV in their transition from paediatric to adult care | Alistair Teague | | Recruiting |
| WISARD | AN OPEN-LABEL, MULTI-CENTRE, RANDOMISED, SWITCH STUDY TO EVALUATE THE VIROLOGICAL EFFICACY OVER 96 WEEKS OF 2-DRUG THERAPY WITH DTG/RPV FDC IN ANTIRETROVIRAL TREATMENTEXPERIENCED HIV-1 INFECTED SUBJECTS VIROLOGICALLY SUPPRESSED WITH NNRTIS RESISTANCE MUTATION K103N. | Laura Waters | | Recruiting |
| LAPTOP | An Open-Label, Multi-Centre, Randomised Study to Investigate Integrase Inhibitor Versus Boosted Protease Inhibitor Antiretroviral Therapy for Patients with Advanced HIV Disease – The Late Presenter Treatment Optimisation Study (LAPTOP) | Robert Miller | | Recruiting |
| PIBIK | A Phase IV Randomised, Open-Label Pilot Study to Evaluate Switching from Protease-Inhibitor based regimen to Bictegravir/Emtricitabine/Tenofovir Alafenamide Single Tablet Regimen in Integrase Inhibitor-naïve, virologically suppressed HIV-1 infected adults harbouring drug resistance mutations | Laura Waters | | Recruiting |
| DOLOMITE | DOLOMITE NEAT ID Network Study: A multi- site observational study to define the safety and effectiveness of Dolutegravir use in HIV positive pregnant women | Sherie Roedling | | Recruiting |
| INTUIT | Interaction Design for Trusted Sharing of Personal Health Data to Live Well with HIV | Jo Gibbs | | Closed for recruitment |
| HIV Bioresource | | Fiona Burns | | Paused |
| Elite Controllers | HIV elite controllers: Comprehensive assessment of host factors associated with HIV-1 elite control | Ravi Gupta | | Paused |
| SALSA | A Phase III, randomized, multicenter, open-label, non-inferiority study evaluating the efficacy, safety and tolerability of switching to dolutegravir/lamivudine fixed dose combination in HIV-1 infected adults who are virologically suppressed | Sarah Pett | | In follow up |
| River | RIVER - Research in Viral Eradication of HIV Reservoirs - a functional cure study | Sarah Pett | | In follow up |
| GS-1489 | GS-US-380-1489: A phase 3, randomised, Double Blind Study to Evaluate the Safety and Efficacy of GS9883/FTC/TAF vs. Triumeq in HIV-1 Infected, Antiretroviral Treatment Naïve Adults | Laura Waters | | In follow up |
| GS-1490 | GS-US-380-1490: A Phase 3, Randomised, Double Blind Study of the Safety and Efficacy of a Fixed Dose combination of GS9883/FTC/TAF vs. DOL/FTC/TAF in HIV-1 infected, Antiretroviral Treatment- Naïve Adults | Laura Waters | | In follow up |
| Merck 021 | MK-1439A-021: Double-Blind, Randomised Trial of Safety and Efficacy of FDC of TDF/3TC/doravirine (MK1439A) Once Daily vs Atripla® in Treatment Naïve HIV-positives | Ian Williams | | In follow up |
| Merck 024 | MK-1439A-024: randomised study evaluating immediate vs deferred switch to FDC of TDF/3TC/doravirine in patients stable and suppressed on a PI/r+2NRTI | Ian Williams | | In follow up |
| Merck 018 | A Phase 3 Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Evaluate the Safety and Efficacy of Doravirine (MK-1439) 100 mg Once Daily Versus Darunavir 800 mg Once Daily plus Ritonavir 100 mg Once Daily, Each in Combination with TRUVADA™ or EPZICOM™/KIVEXA™, in Treatment-Naïve HIV-1Infected Subjects. | Ian Williams | | In follow up |
| POPPY | The POPPY (Pharmacokinetic and clinical Observations in PeoPle over fiftY) Study | Caroline Sabin | | In follow up |
| POPPY Sleep | POPPY Sleep Substudy: study looking at the effects of being HIV positive and being on antiretroviral medication may have on sleeping and sleep pattern | Caroline Sabin | | In follow up |
| START | Strategic Timing of AntiRetroviral Treatment (START): Randomized study to determine whether immediate initiation of antiretroviral treatment (ART) is superior to deferral of ART until the CD4+ declines below 350 cells/mm3 | Ian Williams | | In follow up |
| Eurosida 9 | EuroSIDA Cohort 9: Observational cohort study collecting clinical and demographic data for HIV-positive adults. | Simon Edwards | | In follow up |
| Eurosida 10 | EuroSIDA Cohort X: Observational cohort study collecting clinical and demographic data for coinfected HIV/HCV positive adults. | Simon Edwards | | In follow up |
| FLAIR | FLAIR: A Phase III, Randomized, Multicenter, Parallel-group, Open-Label Study Evaluating the Efficacy and Safety of Long-Acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch from an Integrase Inhibitor Single Tablet Regimen in HIV-1 Infected ART-Naive Adult Participants | Sarah Pett | Nov 2016 - current | In follow up |
| DISCOVER | GS-US-412-2055: A Phase 3, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women Who Have Sex with Men and Are At Risk of HIV-1 Infection | Richard Gilson | | In follow up |
| TANGO | A Phase III, randomized, multicenter, parallel-group, non-inferiority study evaluating the efficacy, safety, and tolerability of switching to dolutegravir plus lamivudine in HIV-1-infected adults who are virologically supressed | Sarah Pett | Apr 2018 - current | In follow up |
| SAFETXT | Safetxt: randomised controlled trial of safer sex intervention delivered through mobile phone messaging | John Saunders | | In follow up |
| MAVMET | MAVMET: a multicentre, 48 week randomised controlled factorial trial of adding Maraviroc and/or Metformin for hepatic steatosis in HIV-1-infected adults on combination antiretroviral therapy | Sarah Pett | | In follow up |
| PETRAM | Understanding changes in treatment-related regional bone turnover using 18F-fluoride-PET/CT in HIV-1-infected men: PETRAM study | Sarah Pett | | In follow up |
| SAFER (UCLH) | | Nina Vora | | In follow up |
| PrEP IMPACT Trial | PrEP IMPACT Trial: A pragmatic health technology assessment of PrEP and implementation. | Richard Gilson | | Completed |
| POPPY LIVER | Hepatic steatosis in people living with HIV older than 50 years of age: The POPPY Hepatic Steatosis Sub-Study | Alejandro Arenas-Pinto | | Completed |
| ECLEAR | Early administration of anti-latency reversing therapy and broadly neutralizing antibodies to limit the establishment of the HIV-1 reservoir during initiation of antiretroviral treatment - a randomized controlled trial (eCLEAR) | Erica Pool | | Completed |
| BESTT | BESTT WOMEN's STUDY: Bone Evaluation in HIV positive women who switch from Truvada/NNRTI to Triumeq | Laura Waters | May 2016 – Apr2020 | Completed |
| VITA | VITA: A randomised controlled trial to assess the clinical and cost effectiveness of topical lactic acid gel for treating second and subsequent episodes of bacterial vaginosis | Richard Gilson | Nov 2017 – Jun 2019 | Completed |
| BRIDGE-IT | A randomised controlled trial to determine the effectiveness of bridging from emergency to regular contraception: The Bridge –it study | Richard Gilson | | Completed |
| PRIME FSH | PRIME Ovarian Biomarker Study: Biomarkers of ovarian ageing in postmenopausal women living with HIV - a prevalence study | Rob Miller/Shema Tariq | | Completed |
| PROUD | PRe-exposure Option for reducing HIV in the UK: an open-label randomisation to immediate or Deferred daily Truvada for HIV negative gay men | Richard Gilson | | Completed |
| H-ART 2 HEART | Deep Cardiovascular Phenotyping of People with HIV on Anti-Retroviral Therapy at risk of Heart Disease | Richard Gilson | | Completed |
| GENAFRICA | Genetic markers of kidney disease progression in people of African heritage in the UK CHIC cohort | Sarah Pett | | Completed |
| CIPHER | CIPHER - study of cognitive function in HIV+ people. | Lewis Haddow | | Completed |
| AMBER | AMBER - randomised, double-blind study to evaluate efficacy and safety of DRV/cobicistat/FTC/TAF vs. DRV/cobicistat fixed dose combination plus Truvada® | Laura Waters | | Completed |
| EMERALD | EMERALD: randomized, active-controlled, open-label study to evaluate the efficacy and safety of switching to a D/C/F/TAF once-daily single-tablet regimen versus continuing the current regimen consisting of a boosted protease inhibitor (bPI) combined with FTC/TDF | Laura Waters | | Completed |
| FLU STUDY | Influenza acquisition in Health Care Workers who work on a dedicated influenza cohort ward | Richard Gilson | | Completed |
| STOP HCV-1 | STOP HCV-1: Stratified Treatment OPtimisation for HCV-1: An open-label randomised controlled trial (RCT) testing biomarker-stratified short-course first-line and re-treatment direct-acting antiviral (DAA) oral treatment regimens to cure mild chronic Hepatitis C (HCV) disease. | Richard Gilson | | Completed |
| PARTNER | PARTNER 2.0: A study in HIV sero-different partnerships to estimate the rate of transmission of HIV and to investigate factors associated with condom use | Richard Gilson | | Completed |
| POSITIVE VOICES | Positive Voices: The national survey of people living with HIV | Richard Gilson | | Completed |
| START | Strategic Timing of AntiRetroviral Treatment (START): Randomized study to determine whether immediate initiation of antiretroviral treatment (ART) is superior to deferral of ART until the CD4+ declines below 350 cells/mm3 | Ian Williams | | Completed |
| HIPVAC | HIPvac: Randomised controlled trial of Imiquimod cream vs. podophyllotoxin in combination with quadrivalent HPV or control vaccination in the treatment and prevention of recurrence of anogenital warts. | Richard Gilson | Feb 2014 - current | Completed |
| SYPHILIS TRANSCRIPTOMICS | Syphilis Transcriptomics: Proof of concept study that aims to utilise next generation sequencing and transcriptomic approaches to understand infection with Treponema pallidum | Patrick French | Oct 2017 - current | Completed |
| HPV SAMPLING | HPV Sampling Study: A study to evaluate the performance of human papillomavirus (HPV) DNA detection in residual specimens taken for Chlamydia trachomatis/Neisseria gonorrhoea nucleic acid amplification testing in men who have sex with men (MSM) | Diarmuid Nugent | Jan 2018 - current | Completed |
| PRIME | PRIME: Quantitative and qualitative study that will exploring the impact of the menopause on HIV-positive women's health and wellbeing | Shema Tariq | Jan 2016 – Oct 2017 | Completed |
| UK HDRD | UK HIV Drug Resistance Database | David Dunn | 2001 – current | Completed |
| GS-1823 | GS-US-292/1823: A Phase 3b, Randomised, Open-Label Study to Evaluate the Safety and Efficacy of Switching from Regimens Consisting of ABC/3TC plus a Third Antiretroviral Agent to the E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infected Adult Subjects | Laura Waters | Sep 2016 – May 2018 | Completed |
| GS-1826 | GS-US-292-1826: A Phase 3b, Randomised, Open-Label Study to Evaluate Switching from a TDF Containing Regimen to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Infected Subjects Aged ≥ 60 Years | Laura Waters | Aug 2016 – Mar 2018 | Completed |
| POPPY NEW WAVE | | Ian Williams | | Upcoming |
| EAGLE | | Richard Gilson | | Upcoming |
| RIO | | Sarah Pett | | Upcoming |
| DEVA | | Richard Gilson | | Upcoming |
| DOR-DOL | | Laura Waters | | Upcoming |
| PREP DLM | | John Saunders | | Upcoming |
| SKIN CANCER QUESTIONNAIRE | | Alejandro Arenas-Pinto | | Upcoming |
| WEIGHT GAIN STUDY | | Alejandro Arenas-Pinto | | Upcoming |
| ANTIMICROBIAL PROPHYLAXIS SURVEY (POPS) | | John Saunders | | Upcoming |
Close